Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET

Company Participants

Wade Walke – Senior Vice President of Investor Relations
Brett Monia – Chief Executive Officer
Eugene Schneider – Chief Clinical Development Officer
Kyle Jenne – Chief Global Product Strategy Officer
Beth Hougen – Chief Financial Officer
Jonathan Birchall – Chief Commercial Officer
Eric Swayze – Executive Vice President of Research
Richard Geary – Chief Development Officer

Conference Call Participants

Gary Nachman – Raymond James
Jessica Fye – JPMorgan
Avi Novick – Morgan Stanley
Yanan Zhu – Wells Fargo Securities
Luca Issi – RBC
David Lebowitz – Citi
Jason Gerberry – Bank of America
Jay Olson – Oppenheimer
Mani Foroohar – Leerink
Andy Chen – Wolfe Research

Operator

Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.

Wade Walke

Thank you, Danielle. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including the reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financials results better represent the economics of our business and how we manage our business. We've also posted the slides on our website that accompany today's call. With me on this morning's call are Brett Monia, our Chief Executive Officer; Eugene Schneider, Chief Clinical Development Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer. Richard Geary, Chief Development Officer; Eric Swayze, Executive Vice President of Research; and Jonathan Birchall, Chief Commercial Officer, will also join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

And with that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning everybody and thank you for joining us on today's call. This is a pivotal time for Ionis. Nearly five years ago, we set out to execute on a new vision focused on bringing our innovative medicines directly to patients in need. And today we're on the cusp of achieving that vision with our first planned independent launch just a few weeks away. Furthermore, we anticipate three additional independent launches over the next three years, positioning Ionis to enter a new era marked by delivering a steady cadence of important new medicines to people with serious diseases.